A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Overload

Trial Profile

A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Overload

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Deferitazole (Primary)
  • Indications Iron overload
  • Focus Pharmacokinetics
  • Sponsors FerroKin BioSciences; Shire
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top